Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson et al. · Journal of Clinical Oncology · 2019 · 591 citations · Full text

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 357 citations · Full text

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

S Kamel, Linda W. Horton, Loïc Ysebaert et al. · Leukemia · 2014 · 225 citations

Inflammation, Thrombosis, Thrombopoiesis +10

Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site

Mohammad O. Khalil, Lindsay M. Morton, Susan S. Devesa et al. · British Journal of Haematology · 2014 · 159 citations · Full text

In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products

Brian C. Foster, S. Vandenhoek, J. Hana et al. · Phytomedicine · 2003 · 144 citations

Marker Substrates, Vitro Inhibition, Biochemistry +10